Impact of Chronic hepatitis C virus genotype 1b infection on triglyceride concentration in serum lipoprotein fractions

International Journal of Molecular Sciences

Volumn 16, Issue 9, 2015, Pages 20576-20594

  Nagano, Tomohisa ^a   Seki, Nobuyoshi ^a   Tomita, Yoichi ^a   Sugita, Tomonori ^a   Aida, Yuta ^a   Itagaki, Munenori ^a   Sutoh, Satoshi ^a   Abe, Hiroshi ^a   Tsubota, Akihito ^b   Aizawa, Yoshio ^a  

^a Jikei University Katsushika Medical Center   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C (CHC); Hepatitis C virus (HCV); Lipoprotein; Triglyceride (TG); Very low density lipoprotein (VLDL); VLDL sub fractions

Indexed keywords

CHYLOMICRON; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HIGH DENSITY LIPOPROTEIN; INTERFERON; INTERFERON LAMBDA 3; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ANTIVIRUS AGENT; BIOLOGICAL MARKER; VERY LOW DENSITY LIPOPROTEIN TRIGLYCERIDE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BLOOD ANALYSIS; FEMALE; GENDER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNE RESPONSE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PARTICLE SIZE; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; COMPLICATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; LIVER CIRRHOSIS; PATHOLOGY; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; BIOMARKERS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIPOPROTEINS; LIPOPROTEINS, VLDL; LIVER CIRRHOSIS; MALE; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84940522084     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160920576     Document Type: Article

References (48)

1. Moriya, K.; Yotsuyanagi, H.; Shintani, Y.; Fujie, H.; Ishibashi, K.; Matsuura, Y.; Miyamura, T.; Koike, K. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J. Gen. Virol. 1997, 78, 1527-1531.
2. Aizawa, Y.; Shimada, N.; Abe, H.; Seki, N.; Aida, Y.; Ishiguro, H.; Ika, M.; Kato, K.; Tsubota, A. Serum lipoprotein profiles and response to pegylated interferon plus ribavirin combination therapy in patients with chronic HCV genotype 1b infection. Hepat. Mon. 2013, 13, e8988.
3. Lange, C.M.; von Wagner, M.; Bojunga, J.; Berg, T.; Farnik, H.; Hassler, A.; Sarrazin, C.; Herrmann, E.; Zeuzem, S. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin. Eur. J. Gastroenterol. Hepatol. 2010, 22, 1303-1307.
4. Maggi, G.; Bottelli, R.; Gola, D.; Perricone, G.; Posca, M.; Zavaglia, C.; Ideo, G. Serum cholesterol and chronic hepatitis C. Ital. J. Gastroenterol. 1996, 28, 436-440.
5. Petit, J.M.; Benichou, M.; Duvillard, L.; Jooste, V.; Bour, J.B.; Minello, A.; Verges, B.; Brun, J.M.; Gambert, P.; Hillon, P. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am. J. Gastroenterol. 2003, 98, 1150-1154.
6. Brown, M.S.; Goldstein, J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232, 34-47.
7. Barth, H.; Liang, T.J.; Baumert, T.F. Hepatitis C virus entry: Molecular biology and clinical implications. Hepatology 2006, 44, 527-535.
8. Huang, H.; Sun, F.; Owen, D.M.; Li, W.; Chen, Y.; Gale, M., Jr.; Ye, J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. USA 2007, 104, 5848-5853.
9. Perlemuter, G.; Sabile, A.; Letteron, P.; Vona, G.; Topilco, A.; Chrétien, Y.; Koike, K.; Pessayre, D.; Chapman, J.; Barba, G.; et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: A model of viral-related steatosis. FASEB J. 2002, 16, 185-194.
10. Yamaguchi, A.; Tazuma, S.; Nishioka, T.; Ohishi, W.; Hyogo, H.; Nomura, S.; Chayama, K. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig. Dis. Sci. 2005, 50, 1361-1371.
11. Serfaty, L.; Andreani, T.; Giral, P.; Carbonell, N.; Chazouillères, O.; Poupon, R. Hepatitis C virus induced hypobetalipoproteinemia: A possible mechanism for steatosis in chronic hepatitis C. J. Hepatol. 2001, 34, 428-434.
12. Moriya, K.; Shintani, Y.; Fujie, H.; Miyoshi, H.; Tsutsumi, T.; Yotsuyanagi, H.; Iino, S.; Kimura, S.; Koike, K. Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. Hepatol. Res. 2003, 25, 371-376.
13. Seki, N.; Sugita, T.; Aida, Y.; Itagaki, M.; Ishiguro, H.; Sutoh, S.; Abe, H.; Tsubota, A.; Matsushima, M.; Aizawa, Y. Assessment of the features of serum apolipoprotein profiles in chronic HCV infection: Difference between HCV genotypes 1b and 2. Hepatol. Int. 2014, 8, 550-559.
14. Furusyo, N.; Ai, M.; Okazaki, M.; Ikezaki, H.; Ihara, T.; Hayashi, T.; Hiramine, S.; Ura, K.; Kohzuma, T.; Schaefer, E.J.; et al. Serum cholesterol and triglyceride reference ranges of twenty lipoprotein subclasses for healthy Japanese men and women. Atherosclerosis 2013, 231, 238-245.
15. Tarantino, G.; Conca, P.; Ariello, M.; Mastrolia, M. Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? Gut 2006, 55, 585.
16. Tarantino, G.; Conca, P.; Sorrentino, P.; Ariello, M. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J. Gastroenterol. Hepatol. 2006, 21, 1266-1268.
17. Siagris, D.; Christofidou, M.; Theocharis, G.J.; Pagoni, N.; Papadimitriou, C.; Lekkou, A.; Thomopoulos, K.; Starakis, I.; Tsamandas, A.C.; Labropoulou-Karatza, C. Serum lipid pattern in chronic hepatitis C: Histological and virological correlations. J. Viral Hepat. 2006, 13, 56-61.
18. Rowell, J.; Thompson, A.J.; Guyton, J.R.; Lao, X.Q.; McHutchison, J.G.; McCarthy, J.J.; Patel, K. Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Hepatol. Int. 2012, 6, 475-481.
19. Mawatari, H.; Yoneda, M.; Fujita, K.; Nozaki, Y.; Shinohara, Y.; Sasaki, H.; Iida, H.; Takahashi, H.; Inamori, M.; Abe, Y.; et al. Association between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1b. J. Viral Hepat. 2010, 17, 274-279.
20. Khattab, M.A.; Eslam, M.; Aly, M.M.; Shatat, M.; Mousa, Y.I.; Abd-Aalhalim, H.; Aly, H.; Shaker, Y. Serum lipids and chronic hepatitis C genotype 4: Interaction and significance. Ann. Hepatol. 2012, 11, 37-46.
21. Hsu, C.S.; Liu, C.J.; Liu, C.H.; Chen, C.L.; Lai, M.Y.; Chen, P.J.; Chen, D.S.; Kao, J.H. Metabolic profiles in patients with chronic hepatitis C: A case-control study. Hepatol. Int. 2008, 2, 250-257.
22. Nishimura, M.; Yamamoto, H.; Yoshida, T.; Seimiya, M.; Sawabe, Y.; Matsushita, K.; Umemura, H.; Sogawa, K.; Takizawa, H.; Yokosuka, O.; et al. Decreases in the serum VLDL-TG/ non-VLDL-TG ratio from early stages of chronic hepatitis C: Alterations in TG-rich lipoprotein levels. PLoS ONE 2011, 25, e17309.
23. Sikorski, J.A. Oral cholesteryl ester transfer protein (CETP) inhibitors: A potential new approach for treating coronary artery disease. J. Med. Chem. 2006, 49, 1-22.
24. Yoshizawa, K.; Abe, H.; Aida, Y.; Ishiguro, H.; Ika, M.; Shimada, N.; Tsubota, A.; Aizawa, Y. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b. J. Med. Virol. 2013, 85, 1180-1190.
25. Icard, V.; Diaz, O.; Scholtes, C.; Perrin-Cocon, L.; Ramière, C.; Bartenschlager, R.; Penin, F.; Lotteau, V.; André, P. Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS ONE 2009, 4, e4233.
26. Stillemark-Billton, P.; Beck, C.; Borén, J.; Olofsson, S.O. Relation of the size and intracellular sorting of apoB to the formation of VLDL 1 and VLDL 2. J. Lipid Res. 2005, 46, 104-114.
27. Shinohara, Y.; Imajo, K.; Yoneda, M.; Tomeno, W.; Ogawa, Y.; Fujita, K.; Kirikoshi, H.; Takahashi, J.; Funakoshi, K.; Ikeda, M.; et al. Hepatic triglyceride lipase plays an essential role in changing the lipid metabolism in genotype 1b hepatitis C virus replicon cells and hepatitis C patients. Hepatol. Res. 2013, 43, 1190-1198.
28. Clark, P.J.; Thompson, A.J.; Zhu, M.; Vock, D.M.; Zhu, Q.; Ge, D.; Patel, K.; Harrison, S.A.; Urban, T.J.; Naggie, S.; et al. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. J. Viral. Hepat. 2012, 19, 332-340.
29. Olubamwo, O.O.; Onyeka, I.N.; Miettola, J.; Kauhanen, J.; Tuomainen, T.P. Hepatitis C as a risk factor for carotid atherosclerosis-A systematic review. Clin. Physiol. Funct. Imaging 2015, 26. doi:10.1111/cpf.12229.
30. Huang, H.; Kang, R.; Zhao, Z. Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis. PLoS ONE 2014, 10, 1371.
31. Adinolfi, L.E.; Zampino, R.; Restivo, L.; Lonardo, A.; Guerrera, B.; Marrone, A.; Nascimbeni, F.; Florio, A.; Loria, P. Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. World J. Gastroenterol. 2014, 20, 3410-3417.
32. Negro, F. Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. J. Hepatol. 2014, 61, S69-S78.
33. Petta, S.; Torres, D.; Fazio, G.; Cammà, C.; Cabibi, D.; di Marco, V.; Licata, A.; Marchesini, G.; Mazzola, A.; Parrinello, G.; et al. Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. Hepatology 2012, 55, 1317-1323.
34. Perticone, M.; Maio, R.; Tassone, E.J.; Tripepi, G.; di Cello, S.; Miceli, S.; Caroleo, B.; Sciacqua, A.; Licata, A.; Sesti, G.; et al. Insulin-resistance HCV infection-related affects vascular stiffness in normotensives. Atherosclerosis 2015, 238, 108-112.
35. Jonsson, J.R.; Barrie, H.D.; O'Rourke, P.; Clouston, A.D.; Powell, E.E. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 2008, 48, 80-87.
36. Vidali, M.; Tripodi, M.F.; Ivaldi, A.; Zampino, R.; Occhino, G.; Restivo, L.; Sutti, S.; Marrone, A.; Ruggiero, G.; Albano, E.; et al. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J. Hepatol. 2008, 48, 399-406.
37. Munteanu, D.; Negru, A.; Radulescu, M.; Mihailescu, R.; Arama, S.S.; Arama, V. Evaluation of bacterial translocation in patients with chronic HCV infection. Rom. J. Intern. Med. 2014, 52, 91-96.
38. Minopetrou, M.; Hadziyannis, E.; Deutsch, M.; Tampaki, M.; Georgiadou, A.; Dimopoulou, E.; Vassilopoulos, D.; Koskinas, J. Hepatitis C virus (HCV)-related cryoglobulinemia: Cryoglobulin type and anti-HCV profile. Clin. Vaccine Immunol. 2013, 20, 698-703.
39. Nakada, Y.; Kurosawa, H.; Tohyama, J.; Inoue, Y.; Ikewaki, K. Increased remnant lipoprotein in patients with coronary artery disease-evaluation utilizing a newly developed remnant assay, remnant lipoproteins cholesterol homogenous assay (RemL-C). J. Atheroscler. Thromb. 2007, 14, 56-64.
40. Takeichi, S.; Yukawa, N.; Nakajima, Y.; Osawa, M.; Saito, T.; Seto, Y.; Nakano, T.; Saniabadi, A.R.; Adachi, M.; Wang, T.; et al. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. Atherosclerosis 1999, 142, 309-315.
41. Barone, M.; Viggiani, M.T.; Amoruso, A.; Schiraldi, S.; Zito, A.; Devito, F.; Cortese, F.; Gesualdo, M.; Brunetti, N.; di Leo, A.; et al. Endothelial dysfunction correlates with liver fibrosis in chronic HCV infection. Gastroenterol. Res. Pract. 2015, 2015, 682174.
42. Simmonds, P.; Mellor, J.; Sakuldamrongpanich, T. Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: Comparison with classifications based upon sequence similarity. J. Gen. Virol. 1996, 77, 3013-3024.
43. Usui, S.; Hara, Y.; Hosaki, S.; Okazaki, M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J. Lipid Res. 2002, 43, 805-814.
44. Okazaki, M.; Usui, S.; Ishigami, M.; Sakai, N.; Nakamura, T.; Matsuzawa, Y.; Yamashita, S. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 578-584.
45. Friedewald, W.T.; Levy, R.I.; Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18, 499-502.
46. Tanaka, Y.; Nishida, N.; Sugiyama, M.; Kurosaki, M.; Matsuura, K.; Sakamoto, N.; Nakagawa, M.; Korenaga, M.; Hino, K.; Hige, S.; et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41, 1105-1109.
47. Sterling, R.K.; Lissen, E.; Clumeck, N.; Sola, R.; Correa, M.C.; Montaner, J.S.; Sulkowski, M.; Torriani, F.J.; Dieterich, D.T.; Thomas, D.L.; et al. Investigators, APRICOT Clinical. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43, 1317-1325.
48. Vallet-Pichard, A.; Mallet, V.; Nalpas, B.; Verkarre, V.; Nalpas, A.; Dhalluin-Venier, V.; Fontaine, H.; Pol, S. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007, 46, 32-36.